Elutia Inc. Cash Flow Conversion Efficiency
Elutia Inc. cash flow conversion efficiency. Based on the latest financial reports, Elutia Inc. (ELUT) has a cash flow conversion efficiency ratio of -0.537x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.46 Million) by net assets ($15.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Elutia Inc. (2018–2025)
Cash flow conversion efficiency of Elutia Inc. from 2018 to 2025. This chart illustrates how Elutia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ELUT share price today for real-time trading data and today's change.
Elutia Inc. Cash Flow Conversion Ratio Explained
Elutia Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Elutia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elutia Inc. ranked by their cash flow conversion efficiency. Also see Elutia Inc. (ELUT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
0.024x |
|
biote Corp
NASDAQ:BTMD
|
-0.081x |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
0.748x |
|
Buima Group
TWO:5543
|
-0.158x |
|
JCH Systems Inc
KQ:033320
|
0.126x |
|
GP Petroleums Limited
NSE:GULFPETRO
|
0.039x |
|
Salter Brothers Emerging Companies Ltd
AU:SB2
|
0.018x |
|
AGRONOMICS LTD.LS-0000001
F:V77
|
N/A |
Annual Cash Flow Conversion Efficiency for Elutia Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Elutia Inc. from 2018 to 2025. Review ELUT free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.67 Million | $-44.81 Million | -1.619x | -430.63% |
| 2024-12-31 | $-46.26 Million | $-22.66 Million | 0.490x | -13.12% |
| 2023-12-31 | $-38.60 Million | $-21.76 Million | 0.564x | -86.76% |
| 2022-12-31 | $-5.03 Million | $-21.43 Million | 4.259x | +472.79% |
| 2021-12-31 | $13.52 Million | $-15.45 Million | -1.142x | -74.64% |
| 2020-12-31 | $20.83 Million | $-13.63 Million | -0.654x | -598.95% |
| 2019-12-31 | $-55.11 Million | $-7.22 Million | 0.131x | +11.03% |
| 2018-12-31 | $-43.41 Million | $-5.12 Million | 0.118x | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more